Ed wears a number of hats [outside of the dunce cap that many think that he has glued to his scalp]. He kicks off the Stem Cell Meeting on the Mesa in La Jolla, CA tomorrow AM. Here is the link. Those who follow Athersys, (shameless plug on my part), another company I follow and have invested a couple of kopek's in, their chairman, Gil Van Bokkelen, a prior Chairman of the ARM, will also speak on progressive stem cell approval policy in Japan and Europe.
A number of other yucky companies like Juno, Bluebird Bio, Editas Medicine, Cellectis and other ne'er do well competitors to Sangamo will also speak. Come to think of it.... 'tis pretty interesting stuff on stem cell tech advances. Stay tuned.
ROGI
==================================================================
9:00am – 9:15am | WELCOME REMARKS |
| Speaker: |
| Edward Lanphier, Chairman, Alliance for Regenerative Medicine; President & CEO, Sangamo BioSciences |
9:15am – 10:15am | PLENARY SESSION: BEYOND CLINICAL PROOF OF CONCEPT What Types of Partnerships & Practices Will be Required for Commercial Success? |
| Given the unique development challenges for gene and cell therapy where a number of technology and process breakthroughs are occurring outside of traditional corporate structures — it is clear that strategic partnerships will play a significant role in moving beyond early clinical signals of efficacy towards versatile and robust models that can support treatment on a larger scale. This panel of pharma and biotech leaders will discuss the large volume of deals in the sector, what is driving them and how these new types of collaborations with non-traditional partners will lead to successful commercial models. |
| Chair: |
| Amy Butler, Ph.D., VP & General Manager, Cell Biology, Thermo Fisher Scientific |
| Speakers: |
| Usman Azam, M.D., Global Head, Cell & Gene Therapies Unit, Novartis |
| Frank Borriello, M.D., Ph.D., VP, Head of Search & Evaluation, Baxalta |
| Olivier Danos, Ph.D., SVP, Gene Therapy, Biogen |
| Perry Karsen, CEO, Celgene Cellular Therapeutics |
| B.G. Rhee, Ph.D., President, Green Cross Holdings |